Therapeutic Strategies After Discontinuation of Valproate By Females with Epilepsy of Child-Bearing Potential: An Insurance Claims Database Study in France and the United Kingdom
Around half of women discontinued valproate successfully, especially if young, with a stabilised disease, with one quarter switching to monotherapy with another ASM, mainly lamotrigine or levetiracetam. Risk factors for unsuccessful discontinuation were identified, which may be useful as 'warning signs' to identify patients who need close follow-up during valproate discontinuation.
Authors
- Laure Carcaillon‐Bentata (ORCID: https://orcid.org/0000-0003-1556-8590)
- Bettina Schmitz (ORCID: https://orcid.org/0000-0002-7700-1584)
- Sandrine Colas
- Juliette Longin
- Sigal Kaplan (ORCID: https://orcid.org/0000-0002-3352-8480)
- Emmanuelle Bignon (ORCID: https://orcid.org/0000-0002-3578-850X)
- Joerg Czekalla
- Magali Rouyer
- Patrick Blin
- Marie‐Agnès Bernard
- David Bigat
- Xinyu Li
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Sanofi (France) (FR)
- Bordeaux Population Health (FR)
- Teva Pharmaceuticals (Israel) (IL)
- Vivantes Klinikum (DE)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1007/s40261-025-01516-w
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Teva Pharmaceutical Industries
- Hexal AG
- Neuraxpharm
- Wockhardt
- Desitin Arzneimittel